Filter By Category
Archives
Share on -
CABIRALIZUMAB
Generic Name: CABIRALIZUMAB
ABSTRACT -
Cabiralizumab (FPA008) is a humanised monoclonal antibody targeting colony-stimulating factor 1 receptor (CSF1R), which drives the differentiation and survival of tumour-associated macrophages (TAMs). By depleting immunosuppressive TAMs from the tumour microenvironment, cabiralizumab aims to restore anti-tumour immune activity. It has been evaluated in combination with nivolumab (anti-PD-1) in Phase I/II trials across multiple solid tumour indications.
DOSAGE -
4 mg/kg intravenously over 30 minutes every 2 weeks in combination with nivolumab; evaluated as per combination trial protocols.
SIDE EFFECTS-
- Oedema (facial and peripheral)
- Elevated liver enzymes
- Fatigue
- Rash
- Nausea
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Infusion-related reactions
- Urticaria
- Angioedema
- Anaphylaxis (rare)
DRUG INTERACTIONS-
- Immune-related adverse events may be amplified when combined with checkpoint inhibitors
- Avoid concurrent systemic corticosteroids unless managing toxicity
- Immunosuppressive drugs may reduce efficacy
PREAUTONS–
- LFT monitoring mandatory — hepatotoxicity has been observed
- Oedema management may require diuretics
- Effective contraception required during treatment
- Not studied in severe hepatic impairment
WARNINGS –
- Periorbital oedema is a characteristic class effect and can be significant
- Immune-mediated hepatotoxicity — discontinue and treat with corticosteroids if severe
- Embryo-foetal toxicity not excluded
Share on -
. Developed by